{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:21:36Z","timestamp":1788956496298,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated. Here, we demonstrate that the reprogramming of lipid metabolism regulates TMZ resistance in patients with pNETs. Via integrated multiomics sequencing, apolipoprotein E (APOE), which is a critical lipid carrier, was identified to be highly increased in the tissue and blood plasma of patients in the TMZ treatment group compared with those in the control group. Further mechanistic studies revealed that TMZ treatment promotes the expression and secretion of APOE, which binds to its surface receptor known as scavenger receptor class B member 1 (SCARB1), thus leading to increased uptake of exogenous lipids to remodel cellular lipid metabolism and activation of the homologous recombination repair (HRR) pathway to repair DNA damage via the \u03b2-catenin-BRCA1\/2 axis. The interruption of APOE-mediated lipid uptake via a SCARB1 inhibitor named as block lipid transport-1 (BLT-1), suppressed TMZ-induced HRR activation and sensitized tumor cells to TMZ treatment in preclinical models, including PDCs, PDOs, and PDXs. In addition, APOE expression levels were shown to be positively correlated with BRCA1\/2 expression in clinical specimens and online databases. This study reveals a new functional role of APOE that leads to chemoresistance in patient treatment. Our findings suggest the potential of combined administration of BLT-1 to overcome TMZ chemoresistance and improve treatments for patients with pNETs.<\/jats:p>","DOI":"10.1038\/s41419-025-08317-1","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:34:55Z","timestamp":1765622095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors"],"prefix":"10.1038","volume":"17","author":[{"given":"Xin","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-9839","authenticated-orcid":false,"given":"Xiaowu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-7143","authenticated-orcid":false,"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-3320","authenticated-orcid":false,"given":"Shunrong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"8317_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"8317_CR2","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-22-3599","volume":"83","author":"J Xu","year":"2023","unstructured":"Xu J, Ye Z, Zhuo Q, Gao H, Qin Y, Lou X, et al. MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression. Cancer Res. 2023;83:2226\u201347.","journal-title":"Cancer Res"},{"key":"8317_CR3","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA: A Cancer J Clin. 2018;68:471\u201387.","journal-title":"CA: A Cancer J Clin"},{"key":"8317_CR4","first-page":"721","volume":"20","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang W, Lou X, Ye Z, Qin Y, Chen J, et al. Recent research hotspots in sequencing and the pancreatic neuroendocrine tumor microenvironment. Cancer Biol Med. 2023;20:721\u20137.","journal-title":"Cancer Biol Med"},{"key":"8317_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamasurg.2013.3376","volume":"148","author":"S Partelli","year":"2013","unstructured":"Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013;148:932\u20139.","journal-title":"JAMA Surg"},{"key":"8317_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","volume":"241","author":"JG Touzios","year":"2005","unstructured":"Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776\u201383.","journal-title":"Ann Surg"},{"key":"8317_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3904\/kjim.2022.100","volume":"37","author":"S Douangprachanh","year":"2022","unstructured":"Douangprachanh S, Joo HJ, Park HM, Han N, Jang HY, Koh YH, et al. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience. Korean J Intern Med. 2022;37:1216\u201322.","journal-title":"Korean J Intern Med"},{"key":"8317_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216769","volume":"588","author":"Z Ye","year":"2024","unstructured":"Ye Z, Li Q, Hu Y, Hu H, Xu J, Guo M, et al. The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes. Cancer Lett. 2024;588:216769.","journal-title":"Cancer Lett"},{"key":"8317_CR9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.3390\/cancers15071955","volume":"15","author":"WH Zhang","year":"2023","unstructured":"Zhang WH, Xu JF, Hu YH, Qin Y, Chen J, Yu XJ, et al. The surgical and therapeutic activities of non-functional pancreatic neuroendocrine tumors at a high-volume institution. Cancers. 2023;15:1955.","journal-title":"Cancers"},{"key":"8317_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189184","volume":"1879","author":"J Jiang","year":"2024","unstructured":"Jiang J, Xu J, Ji S, Yu X, Chen J. Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors. Biochim et Biophys Acta Rev Cancer. 2024;1879:189184.","journal-title":"Biochim et Biophys Acta Rev Cancer"},{"key":"8317_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350\u20134.","journal-title":"N Engl J Med"},{"key":"8317_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"8317_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol : J Am Soc Clin Oncol. 2023;41:1359\u201369.","journal-title":"J Clin Oncol : J Am Soc Clin Oncol"},{"key":"8317_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41663-2","volume":"14","author":"J Yin","year":"2023","unstructured":"Yin J, Wang X, Ge X, Ding F, Shi Z, Ge Z, et al. Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas. Nat Commun. 2023;14:5913.","journal-title":"Nat Commun"},{"key":"8317_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pan.2016.12.013","volume":"17","author":"A Rajabpour","year":"2017","unstructured":"Rajabpour A, Rajaei F, Teimoori-Toolabi L. Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatol : J Int Assoc Pancreatol (IAP) [et al]. 2017;17:310\u201320.","journal-title":"Pancreatol : J Int Assoc Pancreatol (IAP) [et al]"},{"key":"8317_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308417","volume":"11","author":"J Xu","year":"2024","unstructured":"Xu J, Lou X, Wang F, Zhang W, Xu X, Ye Z, et al. MEN1 Deficiency-Driven Activation of the beta-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance. Adv Sci (Weinh). 2024;11:e2308417.","journal-title":"Adv Sci (Weinh)"},{"key":"8317_CR17","doi-asserted-by":"publisher","first-page":"7178","DOI":"10.1200\/JCO.2005.06.502","volume":"23","author":"JA Quinn","year":"2005","unstructured":"Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178\u201387.","journal-title":"J Clin Oncol"},{"key":"8317_CR18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","volume":"27","author":"JA Quinn","year":"2009","unstructured":"Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262\u20137.","journal-title":"J Clin Oncol"},{"key":"8317_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05373-4","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9:2949.","journal-title":"Nat Commun"},{"key":"8317_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-16-1276","volume":"23","author":"F Lin","year":"2017","unstructured":"Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, et al. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res : J Am Assoc Cancer Res. 2017;23:1286\u201398.","journal-title":"Clin Cancer Res : J Am Assoc Cancer Res"},{"key":"8317_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","volume":"35","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, et al. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283\u2013303.","journal-title":"Cell Metab"},{"key":"8317_CR22","doi-asserted-by":"publisher","first-page":"e13694","DOI":"10.1111\/cpr.13694","volume":"57","author":"T Wang","year":"2024","unstructured":"Wang T, Hu Q, Li B, Fan G, Jing D, Xu J, et al. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Cell Prolif. 2024;57:e13694.","journal-title":"Cell Prolif"},{"key":"8317_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112666","volume":"42","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhu L, Qin ZY, Guo Y, Wang S, Xue M, et al. Modulation of cellular metabolism by protein crotonylation regulates pancreatic cancer progression. Cell Rep. 2023;42:112666.","journal-title":"Cell Rep"},{"key":"8317_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"8317_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104\u201316.","journal-title":"Nat Rev Immunol"},{"key":"8317_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00432-014-1634-2","volume":"140","author":"R Anand","year":"2014","unstructured":"Anand R, Prakash SS, Veeramanikandan R, Kirubakaran R. Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis. J cancer Res Clin Oncol. 2014;140:1075\u201385.","journal-title":"J cancer Res Clin Oncol"},{"key":"8317_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cell.2012.10.028","volume":"151","author":"N Pencheva","year":"2012","unstructured":"Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1\/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068\u201382.","journal-title":"Cell"},{"key":"8317_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","volume":"172","author":"MF Tavazoie","year":"2018","unstructured":"Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR\/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172:825\u2013840.e818.","journal-title":"Cell"},{"key":"8317_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ccell.2023.02.004","volume":"41","author":"N Bancaro","year":"2023","unstructured":"Bancaro N, Cal\u00ec B, Troiani M, Elia AR, Arzola RA, Attanasio G, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer cell. 2023;41:602\u2013619.e611.","journal-title":"Cancer cell"},{"key":"8317_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13577-022-00696-3","volume":"35","author":"X Lou","year":"2022","unstructured":"Lou X, Ye Z, Xu X, Jiang M, Lu R, Jing D, et al. Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line. Hum cell. 2022;35:1248\u201361.","journal-title":"Hum cell"},{"key":"8317_CR31","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-22-3599","volume":"83","author":"J Xu","year":"2023","unstructured":"Xu J, Ye Z, Zhuo Q, Gao H, Qin Y, Llou X, et al. MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression. Cancer Res. 2023;83:2226\u201347.","journal-title":"Cancer Res"},{"key":"8317_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.canlet.2020.11.023","volume":"499","author":"M Liu","year":"2021","unstructured":"Liu M, Qin Y, Hu Q, Liu W, Ji S, Xu W, et al. SETD8 potentiates constitutive ERK1\/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Cancer Lett. 2021;499:265\u201378.","journal-title":"Cancer Lett"},{"key":"8317_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47271-y","volume":"15","author":"E Denisenko","year":"2024","unstructured":"Denisenko E, de Kock L, Tan A, Beasley AB, Beilin M, Jones ME, et al. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nat Commun. 2024;15:2860.","journal-title":"Nat Commun"},{"key":"8317_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/1078-0432.CCR-18-0586","volume":"25","author":"KJ Wang","year":"2019","unstructured":"Wang KJ, Wang C, Dai LH, Yang J, Huang H, Ma XJ, et al. Targeting an autocrine regulatory loop in cancer stem-like cells impairs the progression and chemotherapy resistance of bladder cancer. Clin Cancer Res. 2019;25:1070\u201386.","journal-title":"Clin Cancer Res"},{"key":"8317_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18:759\u201372.","journal-title":"Nat Rev Immunol"},{"key":"8317_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0195-5616(03)00004-4","volume":"33","author":"PJ Bergman","year":"2003","unstructured":"Bergman PJ. Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract. 2003;33:651\u201367.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"8317_CR37","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1021\/tx200031q","volume":"24","author":"AE Pegg","year":"2011","unstructured":"Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol. 2011;24:618\u201339.","journal-title":"Chem Res Toxicol"},{"key":"8317_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23:239\u2013254.e236.","journal-title":"Cell Rep"},{"key":"8317_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.molcel.2016.05.021","volume":"62","author":"EM Kass","year":"2016","unstructured":"Kass EM, Moynahan ME, Jasin M. When genome maintenance goes badly awry. Mol cell. 2016;62:777\u201387.","journal-title":"Mol cell"},{"key":"8317_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2012.03.024","volume":"322","author":"C Moncharmont","year":"2012","unstructured":"Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 2012;322:139\u201347.","journal-title":"Cancer Lett"},{"key":"8317_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40495-023-00333-z","volume":"9","author":"C Kishore","year":"2023","unstructured":"Kishore C, Zi X. Wnt signaling and therapeutic resistance in castration-resistant prostate cancer. Curr Pharm Rep. 2023;9:261\u201374.","journal-title":"Curr Pharm Rep"},{"key":"8317_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32119-0","volume":"13","author":"WK Kim","year":"2022","unstructured":"Kim WK, Olson AW, Mi J, Wang J, Lee DH, Le V, et al. Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes. Nat Commun. 2022;13:4364.","journal-title":"Nat Commun"},{"key":"8317_CR43","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/0008-5472.CAN-18-1691","volume":"79","author":"YC Ye","year":"2019","unstructured":"Ye YC, Zhao JL, Lu YT, Gao CC, Yang Y, Liang SQ, et al. NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 2019;79:4160\u201372.","journal-title":"Cancer Res"},{"key":"8317_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2023.114609","volume":"371","author":"T Demby","year":"2024","unstructured":"Demby T, Gross PS, Mandelblatt J, Huang JK, Rebeck GW. The chemotherapeutic agent doxorubicin induces brain senescence, with modulation by APOE genotype. Exp Neurol. 2024;371:114609.","journal-title":"Exp Neurol"},{"key":"8317_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11682-023-00774-6","volume":"17","author":"MM Mulholland","year":"2023","unstructured":"Mulholland MM, Prinsloo S, Kvale E, Dula AN, Palesh O, Kesler SR. Behavioral and biologic characteristics of cancer-related cognitive impairment biotypes. Brain imaging Behav. 2023;17:320\u20138.","journal-title":"Brain imaging Behav"},{"key":"8317_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105915","volume":"175","author":"CAS Ng","year":"2022","unstructured":"Ng CAS, Biran LP, Galvano E, Mandelblatt J, Vicini S, Rebeck GW. Chemotherapy promotes astrocytic response to A\u03b2 deposition, but not A\u03b2 levels, in a mouse model of amyloid and APOE. Neurobiol Dis. 2022;175:105915.","journal-title":"Neurobiol Dis"},{"key":"8317_CR47","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Carpenter ES, Steele NG, Donahue KL, Nwosu ZC, Pacheco A, et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-mediated production of CXCL1. Cancer Res. 2021;81:4305\u201318.","journal-title":"Cancer Res"},{"key":"8317_CR48","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ajpath.2017.06.016","volume":"187","author":"SK Jayakar","year":"2017","unstructured":"Jayakar SK, Loudig O, Brandwein-Gensler M, Kim RS, Ow TJ, Ustun B, et al. Apolipoprotein E promotes invasion in oral squamous cell carcinoma. Am J Pathol. 2017;187:2259\u201372.","journal-title":"Am J Pathol"},{"key":"8317_CR49","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184:2988\u20133005.e2916.","journal-title":"Cell"},{"key":"8317_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcb.2011.11.004","volume":"22","author":"J Wray","year":"2012","unstructured":"Wray J, Hartmann C. WNTing embryonic stem cells. Trends cell Biol. 2012;22:159\u201368.","journal-title":"Trends cell Biol"},{"key":"8317_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cancers8070070","volume":"8","author":"D Hrckulak","year":"2016","unstructured":"Hrckulak D, Kolar M, Strnad H, Korinek V. TCF\/LEF transcription factors: an update from the internet resources. Cancers. 2016;8:70.","journal-title":"Cancers"},{"key":"8317_CR52","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/onc.2012.113","volume":"32","author":"N Alikhani","year":"2013","unstructured":"Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 2013;32:961\u20137.","journal-title":"Oncogene"},{"key":"8317_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04811-2","volume":"22","author":"H Furuya","year":"2024","unstructured":"Furuya H, Sakatani T, Tanaka S, Murakami K, Waldron RT, Hogrefe W, et al. Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. J Transl Med. 2024;22:8.","journal-title":"J Transl Med"},{"key":"8317_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2020.10.048","volume":"501","author":"J Li","year":"2021","unstructured":"Li J, Gao A, Zhang F, Wang S, Wang J, Wang J, et al. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. Cancer Lett. 2021;501:263\u201376.","journal-title":"Cancer Lett"},{"key":"8317_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2025.152895","volume":"230","author":"W Huang","year":"2025","unstructured":"Huang W, Li W, Chen X, Xiang C, Luo K. APOE drives glioma progression by modulating CCL5\/CCR5 signaling in the tumor microenvironment and inducing M2 macrophage polarization. Immunobiology. 2025;230:152895.","journal-title":"Immunobiology"},{"key":"8317_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2025.152900","volume":"230","author":"Z Li","year":"2025","unstructured":"Li Z, Li M, Sun S, Bin Y, Zuo S, Huo R, et al. APOE modulates ferroptosis to drive macrophage polarization toward the M2 type and enhance PTC migration and invasion. Immunobiology. 2025;230:152900.","journal-title":"Immunobiology"},{"key":"8317_CR57","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/17425247.2022.2124967","volume":"19","author":"ID Torres","year":"2022","unstructured":"Torres ID, Loureiro JA, Coelho MAN, Carmo Pereira M, Ramalho MJ. Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance. Expert Opin Drug Deliv. 2022;19:1397\u2013415.","journal-title":"Expert Opin Drug Deliv"},{"key":"8317_CR58","doi-asserted-by":"publisher","first-page":"e62351","DOI":"10.1371\/journal.pone.0062351","volume":"8","author":"M Ito","year":"2013","unstructured":"Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PloS one. 2013;8:e62351.","journal-title":"PloS one"},{"key":"8317_CR59","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.bjc.6604856","volume":"100","author":"SC Naumann","year":"2009","unstructured":"Naumann SC, Roos WP, J\u00f6st E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer. 2009;100:322\u201333.","journal-title":"Br J Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08317-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:02:11Z","timestamp":1768410131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08317-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8317"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08317-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from patients and use of tissue was approved by the Research Ethics Committee of Fudan University Cancer Center (Approval number: SHPCI-PNET-002). All animal experiments were approved by the Institutional Animal Care Committee of Fudan University Cancer Center (Approval number: SHPCI-PNET-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"35"}}